A review of the second-generation antihistamine ebastine for the treatment of allergic disorders

Bibliography

• BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N: Allergic rhinitis and its impact on asthma (ARIA). I Allergy Clin. Immune]. (2001) 108\(Suppl. 5):S147–S334.
   Google Scholar
• ORTONNE JP: Chronic idiopathic urticaria for the generalist. Eur:,l Intern. Med. (2003) 14:148–157.
   PubMedGoogle Scholar
• GREAVES MW: Chronic idiopathic urticaria. Carr: Opin. Allergy Clin. Immune] (2003) 3:363–368.
   PubMedGoogle Scholar
• HANDLEY DA, MAGNETTI A, HIGGINS AJ: Therapeutic advantages of third generation antihistamines. Expert Opin. Investig. Drugs (1998) 7:1045–1054.
   PubMedGoogle Scholar
• VAN CAUWENBERGE P, BACHERT C, PASSALACQUA G et al.: Consensus statement on the treatment of allergic rhinitis. Allergy (2000) 50:116–134.
   Google Scholar
• RATNER, PH, LIM JC, GEORGES GC,and the EBASTINE STUDY GROUP: Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg and placebo in the treatment of seasonal allergic rhinitis. I Allergy Clin. Immune]. (2000) 105:1101–1107.
   PubMed Web of Science ®Google Scholar
• HURST M, SPENCER CM: Ebastine: an update of its use in allergic disorders. Drugs (2000) 59:981–1006.
   PubMed Web of Science ®Google Scholar
• SIMONS FER, SIMONS KJ: Clinical pharmacology of new antihistamine H1 receptor antagonists. Clin. Pharmacekinet. (1999) 36:329–952.
   Google Scholar
• FRANK H JR GILLEN M, ROHATAGI SS et al.: A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. Clin. Pharmacy]. (2002) 42:1097–1104.
   Google Scholar
• MOSS J, MORGANROTH J: Cardiac effects of ebastine and other antihistamines in humans. Drug Sal (1999) 21\(Suppl. 1):69–80.
   Google Scholar
• GILLEN M, PENTIKIS H, RHODES G et al.: Pharmacolkinetic and pharmacodynamic interaction of ebastine and erythromycin (abstract). Clin. Pharmacy]. (1998) 28:878.
   Google Scholar
• ROHATAGI S, GILLEN M, AUBENEAU M et al.: Effect of age and gender on the pharmacolkinetics of ebastine after single and repeated dosing in healthy subjects. Int. J. Clin. Pharmacy]. Ther. (2001) 39:126–134.
   PubMed Web of Science ®Google Scholar
• HUANG MY, ARGENTI D, WILSON J, GARCIA J, HEALD D: Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects. Am. J. Ther. (1998) 5:153–158.
   PubMedGoogle Scholar
• LASSETER KC, DILZER SC, VARGAS R et al.: Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: Phase I open-label study. Chia. Pharmacakinet. (2004) 43:121–129.
   PubMed Web of Science ®Google Scholar
• Investigator's Brochure, Rhone-Poulenc Rorer (Collegeville) 1995 [Data on file].
   Google Scholar
• SIMONS FE: Comparative pharmacology of H1 antihistamines: clinical relevance. Am. J. Med. (2002) 113:38S–46S.
   Google Scholar
• GISPERT J, ANTONIJOAN R, BARBANOJ M et al.: Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges. Ann. Allergy Asthma Immunal (2002) 89:259–264.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, WATSON WT, SIMONS KJ: Pharmacokinetics and pharmacodynamics of ebastine in children. Pediatr. (1993) 122:641–646.
   Web of Science ®Google Scholar
• BOUSQUETJ, GAUDANO EM, PALMA CARLOS AG, STAUDINGER H, and the MULTICENTRE STUDY GROUP: A 12- week, placebo controlled study of efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Allergy (1999) 54:562–568.
   PubMed Web of Science ®Google Scholar
• FROSSARD N, BENABDESSELAM O, PUROHIT A, MOUNDEJI N, PAULI G: Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam. Clin. Pharmacy]. (2000) 14:409–413.
   PubMed Web of Science ®Google Scholar
• GRANT JA, RIETHUISEN JM, MOULAERT B, DE VOS C: A double-blind, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine and placebo: suppression of histamine induced wheal-and-flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma Immunal (2002) 88:190–197.
   PubMed Web of Science ®Google Scholar
• APARICIO S, GRANEL C, RANDAZZO L, VAMENCIA M, OLIVE PEREZ A: Studies of nonsedative antihistamines. II. Assessment of its antihistaminic potency. Allergal Immunapathal (Math) (1992) 20:207–210.
   Google Scholar
• FROSSARD N, VITAL-DURAND D, MOUNEDJI N, VALLETEAU A: Duration of antihistaminic effect after discontinuation of ebastine. Allergy (2001) 56:553–557.
   PubMed Web of Science ®Google Scholar
• GEHANNO P, BREMERD-OURY C, ZEISSER P: Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann. Allergy Asthma Immunal (1996) 76:507–512.
   PubMed Web of Science ®Google Scholar
• STORMS WW: Clinical studies of theefficacy and tolerability of ebastine 10 mg 20 mg daily in the treatment of seasonal allergic rhinitis in the US. Drugs (1996) 52\(Suppl. 1):20–25.
   Google Scholar
• RATNER P, HAMPEL F JR GISPERT J:Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis. Methods Find Exp. Chia. Pharmacy]. (2003) 25:111–115.
   PubMedGoogle Scholar
• VAN STEEKELENBURG J, CLEMENT PAR, BEEL MHL: Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy (2002) 57:346–350.
   PubMed Web of Science ®Google Scholar
• MURRIS-ESPIN M, MELAC M, CHARPENTIER JC, DIDIER A: Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann. Allergy Asthma Immunal (1998) 80(5):399–403.
   PubMed Web of Science ®Google Scholar
• PICADO VALLES C, CADAHIA GARCIA A, CISTERO BAHIMA A, CANO CANTUDO L, SANZ AMARO A, ZAYAS SANZA JM: Ebastine in perennial allergic rhinitis. Ann. Allergy (1991) 67(6):615–618.
   PubMedGoogle Scholar
• BRAUNSTAHL GJ, OVERBEEK SE, KLEINJAN A et al.: Nasal provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. I Allergy Chia. Immunal (2001) 107:469–476.
   PubMed Web of Science ®Google Scholar
• BRAUNSTAHL GJ, KLEINJAN A, OVERBEEK SA et al.: Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am. I Respir. Cr Care Med. (2000) 161:2051-2057. ial ft.
   Google Scholar
• MALICK A, GRANT JA: Antihistamines in the treatment of asthma. Allergy (1997) 52(34 Suppl.):55–66.
   Google Scholar
• WOOD-BAKER R, HOL GATE ST: Do responserelationship of the Hl-histamine antagonist, ebastine, against histamine and metacholine-induced bronchoconstriction in patients with asthma. Agents Actions (1990) 30:284–286.
   PubMedGoogle Scholar
• HORIGUCHI T, TACHIKAWA S, KASAHARA J et al.: Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin. Drug Invest. (1999) 17:435–440.
   Web of Science ®Google Scholar
• MINCARINI M, PASQUALI M, COSENTINO C et al.: Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives.
   Google Scholar
• KALIS B: Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiophatic urticaria in adults. Drugs (1996) 52\(Suppl. 1):30–34.
   Google Scholar
• REUNALA T, BRUMMER- KORVENKONTIO H, PETMAN L, PALOSUO T, SARNA S: Effect of ebastine on mosquito bites. Acta Dermat. Venereol. (1997) 77(4):315–316.
   PubMed Web of Science ®Google Scholar
• KARPPINEN A, PETMAN L, JEKUNEN A et al.: Treatment of mosquito bites with ebastine: a field trial. Acta Derma] Venereal (2000) 80:114–116.
   PubMed Web of Science ®Google Scholar
• KARPPINEN A, KAUTIAINEN H, PETMAN L, BURRI P, REUNALA T: Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. Allergy (2002) 57(6):534–537.
   PubMed Web of Science ®Google Scholar
• HORAK F, STUBNER UP: Comparative tolerability of second generation antihistamines.
   Google Scholar
• VINCENT J, SUMMER DJ, REID IL: Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br. J. Chia. Pharmacy]. (1988) 25:503–508.
   Google Scholar
• WOOSLEY RL: Cardiac actions of antihistamines. Ann. Rev Pharmacy]. Taxical (1996) 36:233–252.
   PubMed Web of Science ®Google Scholar
• HONIG PK, WORTHAM DC, ZAMANI K, CONNER DP, MULLIN JC, CANTILENA LR: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA (1993) 269(12):1513–1518.
   Google Scholar
• GILLEN MS, MILLER B, CHAIKIN P, MORGANROTH J: Effect of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br. J. Clin. Pharmacol. (2001) 52:201–204.
   PubMed Web of Science ®Google Scholar
• MALIK M: Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br. J. Clin. Pharmacy]. (2002) 54(6)682–683.
   Google Scholar
• GISPERT J, ESBRI R, GARCIA E, PERTS F, LURIA X: Ebastine has no effect on QTc interval at dose up to 50 times the therapeutic dose. Allergy (2002) 57\(Suppl. 73):243–244.
   Google Scholar
• ROBERTS DJ:A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Drugs (1996) 52\(Suppl. 1):8–14.
   Google Scholar
• ROBERTS DJ, GISPERT J: The non-cardiac systemic side-effects of antihistamines: ebastine. Clin. Exp. Allergy (1999) 29\(Suppl. 3):151–155.
   Google Scholar
• MATILLA MJ, KUITUNEN T, PLETAN Y: Lack of pharmacodynamic and pharmacokinetic interactions of antihistamine ebastine with ethanol in healthy subjects. Eur. Clin. Pharmacy]. (1992) 43:179–184.
   PubMed Web of Science ®Google Scholar
• MATTILA MJ, ARANKO K, KUITUNEN T: Diazepam effects on the performance of healthy subjects are enhanced by treatment with the antihistamine ebastine. Br. I Clin. Pharmacy]. (1993) 35:272–277.
   PubMed Web of Science ®Google Scholar
• HINDMARCH, SHAMSI Z: The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers. Carr. Med. Res. Opin. (2001) 17:273–281.
   PubMed Web of Science ®Google Scholar
• BROOKHUIS KA, DE VRIES G, DE WAARD D: Acute and subchronic effects of the H1 receptor antagonist ebastine in 10, 20 and 30 mg dose and triprolidine 10 mg on car driving performance. Br. J. Clin. Pharmacy]. (1993) 36:67–70.
   PubMed Web of Science ®Google Scholar
• TAGAWA M, KANO M, OKAMURA N et al.: Differential cognitive effects of ebastine ad (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. Br. J. Clin. Pharmacy]. (2002) 53:296–304.
   PubMed Web of Science ®Google Scholar
• WISEMAN LR, FAULDS D: Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs (1996) 51:260–277.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J: Antihistamines in severe/chronic rhinitis. Clin. Exp. Allergy (1998) 28\(Suppl. 6):49–53.
   Google Scholar